Maladie thrombo-embolique veineuse au cours du cancer. Indication des héparines de bas poids moléculaires

Levitan, 1999, Rates of initial and recurrent thromboembolic disease among patient with malignancy versus those without malignancy. Risk analysis using Medicare claims data, Medicine (Baltimore), 78, 285, 10.1097/00005792-199909000-00001 Anderson, 2007, Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism, Am J Hematol, 82, 777, 10.1002/ajh.20983 Mismetti, 2010, Recommandations de bonne pratique : prévention et traitement de la maladie thromboembolique veineuse en médecine, J Mal Vasc, 35, 127, 10.1016/j.jmv.2009.12.002 Meyer, 2002, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study, Arch Intern Med, 162, 1729, 10.1001/archinte.162.15.1729 Lee, 2003, N Engl J Med, 349, 146, 10.1056/NEJMoa025313 Hull, 2006, LITE trial investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer, Am J Med, 119, 1062, 10.1016/j.amjmed.2006.02.022 Lee, 2015, CATCH investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial, JAMA, 314, 677, 10.1001/jama.2015.9243 Kearon, 2012, Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th consensus: American College of Chest Physician evidence based clinical practice guidelines, Chest, 14, e419S, 10.1378/chest.11-2301 Farge, 2013, International clinical guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, J Thromb Haemost, 11, 56, 10.1111/jth.12070 Easaw, 2015, Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment, Curr Oncol, 22, 144, 10.3747/co.22.2587 Kearon, 2016, Antithrombotic therapy for VTE disease, Chest, 149, 315, 10.1016/j.chest.2015.11.026 Noble, 2015, Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology, Haematologica, 100, 1486, 10.3324/haematol.2015.127126 Vedovati, 2015, Direct oral anticoagulations in patients with venous thromboembolism and cancer: a systematic review and meta-analysis, Chest, 147, 475, 10.1378/chest.14-0402 Francis, 2015, Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study, J Thromb Haemost, 13, 1028, 10.1111/jth.12923 Napolitano, 2014, Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the cancer-DACUS study, J Clin Oncol, 32, 3607, 10.1200/JCO.2013.51.7433 Debourdeau, 2013, International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheter in patients with cancer, J Thromb Haemost, 11, 71, 10.1111/jth.12071 Frere, 2014, Therapy for cancer-related thromboembolism, Semin Oncol, 41, 319, 10.1053/j.seminoncol.2014.04.005 Khorana, 2008, Development and validation of a predictive model for chemotherapy-associated thrombosis, Blood, 111, 4902, 10.1182/blood-2007-10-116327 Louzada, 2012, Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism, Circulation, 126, 448, 10.1161/CIRCULATIONAHA.111.051920 Carrier, 2009, Dose escalation of low molecular weigth heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients, J Thromb Haemost, 7, 760, 10.1111/j.1538-7836.2009.03326.x Debourdeau, 2015, Méthodes d’élaboration des recommandations pour la pratique clinique (RPC) et fonctionnement de la plate-forme cœur vaisseaux cancer (PTF-CVC) dans l’inter3C Vaucluse pays d’Arles, Bull Cancer, 10.1016/j.bulcan.2015.08.002 Bergmann, 2010, Endorse investigators. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The Endorse global survey, Thromb Haemost, 103, 736, 10.1160/TH09-09-0667 Mahé, 2014, Cancer et récidive thromboembolique veineuse : non-respect des recommandations de traitement, Bull Cancer, 101, 295, 10.1684/bdc.2014.1907 Sevestre, 2014, Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study, J Mal Vasc, 39, 161, 10.1016/j.jmv.2014.03.001 Farge, 2015, RIETE Investigators. Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism, Medicine (Baltimore), 94, e1235, 10.1097/MD.0000000000001235 Meyer, 2011, Effet de la tinzaparine sur la mortalité du cancer bronchique non à petites cellules opéré, Rev Mal Respir, 28, 654, 10.1016/j.rmr.2011.03.015 Macbeth, 2016, Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial, J Clin Oncol, 34, 488, 10.1200/JCO.2015.64.0268